Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.

AIMS The aim of the study was to investigate the pharmacokinetics of recombinant human interleukin-2 (rhIL-2) in patients with metastatic renal cell carcinoma following different subcutaneous (s.c.) administration regimens. METHODS RhIL-2 was administered subcutaneously to 10 patients according to two different dosing regimens: group A received 20 x 10(6) IU m(-2) once daily and group B 10 x 10(6) IU m(-2) twice daily (every 12 h). Additionally, in all patients the influence of soluble interleukin-2 receptor (sIL-2R) on the pharmacokinetics of rhIL-2 was investigated. RESULTS The mean area under the serum concentration-time curve to 24 h (AUC(0,24 h)) was 627 IU ml(-1) h in treatment group A and 1130 IU ml(-1) h (P=0.029) in treatment group B. In both study groups Cmax and AUC(0,12 h) were not significantly different. Seventy-two hours after the beginning of s.c. rhIL-2 therapy the sIL-2R increased significantly (P=0.016), and sIL-2R levels over 1200 pmol l(-1) seemed to reduce the AUC. CONCLUSIONS In patients with metastatic renal cell cancer administration of 20 x 10(6) IU m(-2) of rhIL-2 s.c. in two daily doses (10 x 10(6) IU m(-2) every 12 h) provides better bioavailability and is preferable to the single dose administration.

[1]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[2]  H. Kirchner,et al.  Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. , 1991, Cancer research.

[3]  W. Evans,et al.  Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. , 1995, Journal of pharmaceutical sciences.

[4]  J. Symons,et al.  Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. , 1988, Journal of immunology.

[5]  H. Kirchner,et al.  Soluble interleukin 2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells. , 1994, Cytokine.

[6]  W. Evans,et al.  Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. , 1992 .

[7]  H. Mohr,et al.  Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. , 1990, Molecular biotherapy.

[8]  Kendall A. Smith,et al.  Interleukin-2: inception, impact, and implications. , 1988, Science.

[9]  A. Capron,et al.  Levels of soluble IL‐2 receptor in plasma from asthmatics. Correlations with blood eosinophilia, lung function, and corticosteroid therapy , 1992, Clinical and experimental immunology.

[10]  H. Kawasaki,et al.  Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders. , 1997, International journal of hematology.

[11]  P. Fauchald,et al.  Renal replacement therapy in elderly patients , 1988, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  B. Østenstad Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer. , 1992 .

[13]  N. Mulder,et al.  Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Diamantstein,et al.  Demonstration of two distinct forms of released low‐affinity type interleukin 2 receptors , 1988, European journal of immunology.

[15]  M. Chilosi,et al.  Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. , 1992, Cellular immunology.

[16]  T. Waldmann The IL-2/IL-2 receptor system: a target for rational immune intervention. , 1993, Trends in pharmacological sciences.

[17]  H. Kirchner,et al.  alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. , 1991, Seminars in oncology.

[18]  A. Scarpa,et al.  Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. , 1987, Blood.

[19]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[20]  G. May,et al.  A critical analysis of soluble interleukin-2 receptor levels in kidney allograft recipients. , 1996 .

[21]  S. Rosenberg,et al.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. , 1981, Cancer research.

[22]  J. Soulillou,et al.  A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. , 1987, Journal of immunology.

[23]  P W Mansell,et al.  Pharmacokinetics of recombinant interleukin 2 in humans. , 1990, Cancer research.

[24]  J. Thompson,et al.  Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. , 1987, Cancer research.

[25]  H. Kirchner,et al.  Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies , 1990, The Lancet.

[26]  R. Fernandez-Botran Soluble cytokine receptors: their role in immunoregulation , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  S. Ziegler,et al.  Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. , 1993, Science.

[28]  S. Rosenberg,et al.  Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. , 1986, Cancer research.

[29]  T. Honjo,et al.  A soluble 'anchorminus' interleukin 2 receptor suppresses in vitro interleukin 2-mediated immune responses. , 1988, Immunology Letters.

[30]  W. Leonard,et al.  A secreted form of the human interleukin 2 receptor encoded by an "anchor minus" cDNA. , 1986, Journal of immunology.